Skip to main content
OpenTrials
Completed

NCT Number: NCT06329661

A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

CYS-007 Investigational Site, Newport Beach, California, United States

Loading trial locations.

About this study

The effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell density (cells/mm²) will be evaluated in comparison to a hypotonic saline solution in subjects with DED after 12 months of treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be at least 18 years of age;
  • Provide written informed consent;
  • Have a subject reported history of dry eye disease (DED) in both eyes
  • Be able and willing to follow instructions, including participation in all trial assessments and visits.

Exclusion criteria

  • Be a woman who is pregnant, nursing, or planning a pregnancy;
  • Unwillingness to to use acceptable means of birth control
  • Clinically significant slit-lamp findings or abnormal lid anatomy at screening
  • Ongoing ocular or systemic infection at screening or baseline
  • Presence of uncontrolled systemic diseases
  • Presence of known allergy and/or sensitivity to the study drug or its components
  • Intraocular surgery or ocular laser surgery or significant trauma within 365 days before Visit 1, or have any planned ocular surgeries during the trial period
  • Have a condition or be in a situation which the Investigator feels may put the subject at significant risk, may confound the trial results, or may interfere with the subject's participation in the trial significantly.
  • Randomized in a previous CyclASol trial

Treatment and study plan

Cyclosporine ophthalmic solution, 0.1%

Drug

Colorless and clear opthalmic solution containing 0.1% Cyclosporine

Other names: VEVYE

Saline solution, 0.6%

Drug

Colorless and clear sodium chloride solution (0.6%)

Primary outcomes

  1. Change From Baseline in Corneal Endothelial Cell Density (ECD)

    Time frame: 12 months

    Change from baseline at 12 months in ECD measured as count/mm2 using specular microscopy in the study eye

Sponsors and collaborators

Lead sponsor

Novaliq GmbH

Industry

Registry information

Official study title

A Multi-center, Randomized, Double-masked, Controlled Clinical Trial to Evaluate the Corneal Endothelial Health of Dry Eye Disease Subjects Treated With Cyclosporine Ophthalmic Solution, 0.1%

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 26, 2024
Registry last updated
Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.